FDA Announces Sweeping New Vaccine Approval Rules After Internal Review Flags Child Deaths

In a major shake‑up of U.S. vaccine policy, the U.S. Food and Drug Administration (FDA) said it will impose significantly tighter standards for vaccine approvals, citing an internal review that found a possible link between COVID‑19 vaccines and at least 10 deaths among children.

According to a memo from the agency’s vaccine‑oversight division, the deaths are tentatively attributed to myocarditis, a rare inflammation of the heart. The report has not yet been published in a peer‑reviewed journal or disclosed publicly in full.

As a result, FDA leaders, including Vinay Prasad and Marty Makary, announced a new regulatory framework that will require manufacturers to provide more robust evidence — including larger, randomized clinical trials — before vaccines are cleared for general use.

Under the new rules, the agency plans to:

• Reassess multi‑vaccine schedules and simultaneous vaccinations.
• Demand that vaccine developers demonstrate real-world reduction in disease, not just immune response (e.g., antibody levels).
• Increase scrutiny of vaccination rates among pregnant women, children, and other vulnerable populations.

The change marks a sharp departure from prior FDA policy, under which many vaccines — including annual respiratory vaccines such as for COVID-19 and flu — were often approved on immunogenicity endpoints (how well they triggered immune responses) rather than direct evidence of disease prevention.

The announcement comes just months after the FDA limited the use of certain updated COVID‑19 vaccines. In August 2025, the agency approved new formulations but restricted eligibility broadly to older adults or younger individuals with specific risk factors.

Supporters of the stricter approach say it will improve public trust in vaccines by ensuring that only products with proven, long-term safety and effectiveness reach the general population. FDA Commissioner Makary, in a public statement, criticized the prior “rubber‑stamp” approach, calling it “a mockery of science.”

But the announcement immediately stirred controversy among public health experts. Critics warned that the evidence linking the vaccines to child deaths remains unpublished and unverified. Some expressed concern the move could slow down vaccine development, impair timely access to protective shots, and undermine established immunization programs.

As the debate unfolds, many await the release of the whole internal report and peer‑reviewed data — while observing how the new FDA rules reshape the United States’ immunization landscape.

Sources:

• Reuters
• BioPharma Dive
• WVIA
• PBS
• U.S. Food and Drug Administration
• The Guardian
• The Washington Post
• Wall Street Journal